REBEL: A Phase 1b Study on the Safety and Feasibility of External Beam Radiotherapy Followed by Bispecific Antibody Therapy for Relapsed/Refractory DLBCL
University of Utah
Summary
The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
Eligibility
- Age range
- 18+ years
- Sex
- All
- Healthy volunteers
- No
Inclusion Criteria: * Participant aged ≥ 18 years * Disease criteria: * Histologically confirmed large b-cell lymphoma (LBCL), including DLBCL not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma with: * Relapsed or refractory disease with at least 2 prior systemic therapies * Must be a candidate for radiation therapy up to 20 Gy. Radiation therapy to up to 3 lesions will be permitted. * Must have at minimum two sites of evaluable disease per Lugano 2014, including one site that will not be irradiated as part of this study and has not re…
Interventions
- DrugEpcoritamab
Epcoritamab will be administered per standard of care.
- DrugGlofitamab
Glofitamab will be administered per standard of care.
- RadiationExternal Beam Radiation Therapy
Participants will receive radiation therapy for 5 fractions completed on sequential days.
Location
- Huntsman Cancer Institute at University of UtahSalt Lake City, Utah